Large-Scale Screening of EGFR Mutations in the Blood of Advanced NSCLC Patients Is Feasible to Guide Treatment.
In a significant percentage of advanced NSCLC patients, tumor tissue is unavailable or insufficient for genetic analyses. A prospective study was designed to evaluate use of circulating free DNA (cfDNA) purified from blood of patients with advanced NSCLC to detect mutations of EGFR. Patients treated with EGFR inhibitors based on mutations detected by cfDNA were found to […]
